Clinical trials: Breast Cancer
Vulvodynia, Dyspareunia
Therapy to Prevent Sexual Pain in Breast Cancer Survivors
The purpose of this protocol is to determine whether pain with sexual intercourse can be reduced in menopausal, breast cancer survivors and to evaluate the effectiveness of a non-hormonal therapy (Lidocaine Liquid) vs.
- Conditions
- Vulvodynia, Dyspareunia, Breast Cancer, Menopause
- Trial name
- NCT01539317
- Testing
- Topical liquid lidocaine, Topical saline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the…
- Trial name
- e3 (NCT01674140)
- Testing
- anastrozole, everolimus, exemestane
- Where
- 1,458 sites in United States, Puerto Rico
- Volunteers
- 1,939 people
- Sponsor
- SWOG Cancer Research Network
Head and Neck Cancer, Liver Cancer
A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors
This is a phase Ib open label, expansion study of CUDC-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors.
- Conditions
- Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT01171924
- Testing
- CUDC-101
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Curis, Inc.
Breast Carcinoma, Colorectal Carcinoma
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer…
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT04905082
- Testing
- Best Practice, Educational Intervention, Genomic Profile
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- City of Hope Medical Center
Receptors, Estrogen, Genes, Erbb-2
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2…
- Conditions
- Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
- Trial name
- NCT04288089
- Testing
- Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Eisai Inc.
Breast Neoplasms
Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma
The purpose of this study is to determine if Mammosite Catheter optimization using multiple dwell position delivery decreases skin toxicity over historically reported skin toxicity with the single dwell delivery method.
- Trial name
- Mammosite (NCT00611624)
- Testing
- Mammosite brachytherapy radiation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Breast Cancer
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
Radiotherapy has been shown to reduce breast-cancer specific mortality in patients at high risk for distant dissemination. It has also been shown to increase rates of non-breast cancer deaths and morbidity due to cardiovascular…
- Trial name
- NCT00581256
- Testing
- IMRT, 3D
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Neoplasms
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer.
- Trial name
- TEAM (NCT00036270)
- Testing
- exemestane (Aromasin), tamoxifen + exemestane
- Where
- 179 sites in United States
- Volunteers
- 9,779 people
- Sponsor
- Pfizer
Arthralgia
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body.
- Trial name
- NCT00111241
- Testing
- aromatase inhibitors (letrozole, anastrozole)
- Where
- Australia
- Volunteers
- 115 people
- Sponsor
- Monash University
Melanoma, Non-small Sell Lung Cancer (NSCLC)
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v.
- Conditions
- Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer
- Trial name
- NCT02404441
- Testing
- PDR001
- Where
- 41 sites in United States, Canada and 12 more
- Volunteers
- 319 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with hormone therapy in Indian women with advanced breast cancer.
- Trial name
- NCT04707196
- Testing
- Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI), Fulvestrant
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Gynecologic Cancer
Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer
The objectives of this study are to: 1) adapt a mindfulness-based therapy program designed to help women manage their sexual and body image concerns after cancer (Mindful After Cancer, MAC) to a videoconference format and 2)…
- Trial name
- MAC (NCT04559854)
- Testing
- Mindful After Cancer
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Oregon State University
Breast Cancer Nos Metastatic Recurrent
Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.
Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions. Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point.
- Trial name
- NCT01703754
- Testing
- Ad-RTS-hIL-12 and Veledimex, Palifosfamide
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Breast Cancer
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
This is a two-arm, randomized, double-blind, multicenter, pre-operative study to evaluate the effect of combining letrozole and GDC-0032 (also known as taselisib) versus letrozole and placebo in postmenopausal women with estrogen…
- Trial name
- NCT02273973
- Testing
- Letrozole, Taselisib
- Where
- 117 sites in United States, Australia and 20 more
- Volunteers
- 334 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery…
- Trial name
- NCT02955394
- Testing
- Enzalutamide, Fulvestrant
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Colorado, Denver
Breast Neoplasms
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast…
- Trial name
- NCT00076024
- Testing
- Docetaxel, AG-013736 (axitinib)
- Where
- 54 sites in United States, Canada and 6 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Breast Cancer
Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy
This research study involves the use of a common breast imaging modality (magnetic resonance imaging, 'MRI') and is investigating its role in evaluating surgical decision making for breast cancer when it is performed with the…
- Trial name
- NCT02956473
- Testing
- Supine MRI, Neoadjuvant Therapy (NAT), Ultrasound
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer of Breast
Aging Mammary Stem Cells and Breast Cancer Prevention
To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens
- Trial name
- NCT02642094
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- LuZhe Sun
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients…
- Trial name
- NCT04467515
- Testing
- CAM-H2
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Precirix